Last update 16 Apr 2025

BZE-2204

Overview

Basic Info

Drug Type
CAR-T
Synonyms
CD19/​CD22/​BCMA CAR-T(Shanghai Cell Therapy Group), BZE 2204, BZE2204
Target
BCMA x CD19 x CD22
Action
inhibitors
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Relapse multiple myelomaB-cell lymphoma refractoryNon-Hodgkin Lymphoma
Inactive Indication-
Originator Organization
Shanghai Cell Therapy Group Co., Ltd.Shanghai Cell Therapy Group Co., Ltd.
Active Organization
Chantibody Therapeutics, Inc.Chantibody Therapeutics, Inc.Shanghai Cell Therapy Group Co., Ltd.Shanghai Cell Therapy Group Co., Ltd.
Inactive Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with BZE-2204
NCT06732232
/ RecruitingEarly Phase 1
A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma
NCT06446128
/ Active, not recruitingEarly Phase 1
A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
100 Clinical Results associated with BZE-2204
Login to view more data
100 Translational Medicine associated with BZE-2204
Login to view more data
100 Patents (Medical) associated with BZE-2204
Login to view more data
100 Deals associated with BZE-2204
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 1
China
Shanghai Cell Therapy Group Co., Ltd.Shanghai Cell Therapy Group Co., Ltd.
12 Dec 2024
B-cell lymphoma refractoryPhase 1
China
Shanghai Cell Therapy Group Co., Ltd.Shanghai Cell Therapy Group Co., Ltd.
01 Apr 2024
Non-Hodgkin LymphomaPreclinical
United States
Chantibody Therapeutics, Inc.Chantibody Therapeutics, Inc.
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free